Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genmab ( (GMAB) ) just unveiled an update.
On December 29, 2025, Genmab announced it would discontinue further clinical development of acasunlimab following a portfolio review and assessment of a more competitive market landscape. Although the company described the drug’s clinical profile to date as encouraging, management said it will redirect resources toward late-stage programs it sees as having higher potential impact, notably EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan (Rina-S). The move underscores Genmab’s disciplined approach to portfolio prioritization and capital allocation, and the company emphasized that the decision will not affect its full-year 2025 financial guidance, reassuring investors that its broader pipeline momentum and financial outlook remain intact.
The most recent analyst rating on (GMAB) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody-based medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, Denmark, the company has built a broad portfolio of antibody formats including bispecific antibodies, antibody–drug conjugates and immune-modulating antibodies, powering eight approved antibody medicines and a strong late-stage clinical pipeline, with operations across North America, Europe and Asia Pacific.
Average Trading Volume: 2,058,063
Technical Sentiment Signal: Buy
Current Market Cap: $20.63B
Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.